Related Experiment Video
Updated: Jan 30, 2026
05:54
A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
Published on: December 29, 2017
10.5K
MDX-060. Medarex
1The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia.
Current Opinion in Investigational Drugs (London, England : 2000)
|December 24, 2005
Abstract:
Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
Insights
Medarex is developing MDX-060, an antibody therapy targeting CD30+ lymphomas like Hodgkin's disease. Early-stage clinical trials were in progress by late 2002.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- CD30-positive lymphomas represent a significant group of hematologic malignancies.
- Targeted antibody therapies offer a promising approach for treating these cancers.
Purpose of the Study:
- To evaluate the safety and efficacy of MDX-060, a novel antibody, in patients with CD30+ lymphomas.
- To assess the potential of MDX-060 as a treatment for Hodgkin's disease and anaplastic large cell lymphomas.
Main Methods:
- Development of the antibody MDX-060 by Medarex.
- Initiation of Phase I/II clinical trials to assess safety and preliminary efficacy.
- Focus on patient populations with CD30-expressing lymphomas.
Main Results:
- Phase I/II clinical trials were underway as of December 2002.
- Data on safety, tolerability, and preliminary efficacy were being collected.
Conclusions:
- MDX-060 demonstrated potential as a targeted therapy for CD30+ lymphomas.
- Further clinical investigation was warranted based on early trial progress.
